Last reviewed · How we verify

NVP Healthcare — Portfolio Competitive Intelligence Brief

NVP Healthcare pipeline: 0 marketed, 0 filed, 5 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 5 Phase 3 0 Phase 2 18 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
NVP-2203-R3 NVP-2203-R3 phase 3 PD-1 inhibitor PD-1 Oncology
NVP-2203-R1 NVP-2203-R1 phase 3 SGLT2 inhibitor SGLT2 Diabetes
NVP-2203-R2 NVP-2203-R2 phase 3 SGLT2 inhibitor SGLT2 Diabetes
NVP-1203-R NVP-1203-R phase 3 PD-1 inhibitor PD-1 Oncology
NVP-2203 NVP-2203 phase 3 PD-1 inhibitor PD-1 Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Beijing Tiantan Hospital · 2 shared drug classes
  2. CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 2 shared drug classes
  3. Ahn-Gook Pharmaceuticals Co.,Ltd · 2 shared drug classes
  4. Asan Medical Center · 2 shared drug classes
  5. BioRay Pharmaceutical Co., Ltd. · 2 shared drug classes
  6. CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · 2 shared drug classes
  7. Addpharma Inc. · 2 shared drug classes
  8. CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for NVP Healthcare:

Cite this brief

Drug Landscape (2026). NVP Healthcare — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/nvp-healthcare. Accessed 2026-05-17.

Related